Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laroprovstat/rosuvastatin fixed-dose combination in treatment-naive hypercholesterolaemia
2026-525642-30-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of laroprovstat and rosuvastatin in hypercholesterolemia (6 arms), sponsored by AstraZeneca. Primary endpoint: Relative change in LDL-C at 8 weeks. Planned start Oct 2026; status: authorised.
02
Drugs
laroprovstatrosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2026-525642-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525642-30-00.